Stocks and Investing
Stocks and Investing
Thu, May 16, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Reiterated (VRCA) at Strong Buy and Held Target at $16 on, May 16th, 2024
Serge Belanger of Needham, Reiterated "Verrica Pharmaceuticals Inc." (VRCA) at Strong Buy and Held Target at $16 on, May 16th, 2024.
Serge has made no other calls on VRCA in the last 4 months.
There is 1 other peer that has a rating on VRCA. Out of the 1 peers that are also analyzing VRCA, 0 agree with Serge's Rating of Hold.
This is the rating of the analyst that currently disagrees with Serge
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $14 on, Tuesday, May 14th, 2024
Contributing Sources